BRADENTON, Fla., Aug. 6, 2025 /PRNewswire/ — Continuity Biosciences, a company pioneering next-generation combination product drug delivery, today announced the appointment of two highly distinguished leaders to its Board of Directors: Josephine M. Torrente, Director at Hyman, Phelps & McNamara, P.C., and Dr. Joseph M. DeSimone, serial entrepreneur and professor at Stanford University. These appointments mark a significant step forward in Continuity’s mission to advance transformative drug delivery technologies, supported by world-class regulatory expertise and materials science innovation.

Josephine M. Torrente

• Current Role: Director, Hyman, Phelps & McNamara, P.C., the largest dedicated FDA regulatory law firm in the U.S.
• Experience: Over 30 years advising pharmaceutical and biotechnology companies on FDA regulatory strategy, product development, and lifecycle management
• Strategic Contribution: Ms. Torrente’s deep regulatory insight will guide Continuity’s clinical development and FDA engagement strategies as the company scales its pipeline

Dr. Joseph M. DeSimone

• Current Role: Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering, Stanford University
• Honors and Recognition: National Medal of Technology and Innovation recipient; inventor on 200+ patents; author of 350+ scientific publications; One of only 25 people elected into all three US National Academies- Science, Engineering and Medicine
• Entrepreneurial Leadership: Co-founder of Carbon (developer of CLIP 3D printing); founder of Focal Medical (acquired by Continuity) and PinPrint, a 3D microdispensing platform in which Continuity has made a strategic investment
• Strategic Contribution: Dr. DeSimone’s expertise in materials science, digital manufacturing, and drug delivery perfectly aligns with Continuity’s platform focus on localized, precision therapeutics

Executive Commentary

“We are honored to welcome Josephine and Joe to our Board,” said Bob Whitehead, Co-Founder and Executive Chairman of Continuity Biosciences. “Josephine’s regulatory acumen and clear-eyed judgment are second to none. Joe is not only a visionary in drug delivery but also a trusted partner in our efforts through Focal Medical and PinPrint. Their expertise will be instrumental as we continue to scale our programs and build long-term value.”

Torrente and DeSimone join Continuity’s existing Board of Directors, which includes Bob Whitehead and Ramakrishna Venugopalan, PhD, MBA (Continuity’s co-founders), Monica Reed, MD, Mike Fowler, and Allen Weiss.

• Krishna Venugopalan formerly led combination product development at AbbVie, contributing to flagship therapies Skyrizi and the newly launched Vyalev—both high-impact combination products
• Mike Fowler is CEO of Affordable Housing Partners, Inc., which is a subsidiary of Berkshire Hathaway
• Allen Weiss served as the President of Worldwide Operations for Walt Disney Parks and Resorts (now known as Disney Parks, Experiences and Products)
• Monica Reed is CEO of UChicago Medicine AdventHealth, where she oversees the strategic development and growth of the health system’s Great Lakes Region, including four hospitals and more than 50 sites of care

About Continuity Biosciences

Founded in 2024, Continuity Biosciences is developing advanced delivery platforms for biologics and complex therapeutics, with a focus on precision targeting and tunable release. Operating in Houston (TX), Raleigh (NC), Bradenton (FL), and Torino (Italy), Continuity’s pipeline spans oncology, metabolic diseases, infectious diseases, and women’s health. Through strategic acquisitions—including Focal Medical—and targeted investments like PinPrint, Continuity is building a differentiated platform to transform the delivery of challenging therapeutics.

PARIS, Aug. 6, 2025 /PRNewswire/ — HR Path, a global leader in HR consulting and HRIS solutions, is proud to announce its strategic acquisition of PredictiveHR, a U.S.-based company renowned for its deep expertise in HRIS advisory and implementation services, with a strong specialization in UKG solutions.

With a presence in 28 countries and a team of over 2,500 professionals, HR Path is a trusted partner for businesses navigating the complexities of Human Resources. Specializing in advisory, implementation, and operational services, HR Path delivers cutting-edge solutions designed to enhance efficiency and foster growth. Since it was founded in 2001, the company has stayed true to its mission of reshaping HR practices around the world.

Since 2016, PredictiveHR has been a trusted professional services partner for organizations leveraging HR technology platforms like UKG and Paylocity. With over a century of combined consulting experience, we specialize in implementation, optimization, and post-live support services that drive adoption, streamline operations, and deliver measurable results. PredictiveHR helps clients unlock the full potential of their HCM investments through strategic, hands-on expertise and white-glove service delivery.

This acquisition marks a significant milestone for HR Path, reinforcing its leadership in the HR industry and strengthening its footprint in the North American market. PredictiveHR’s dedicated focus on UKG implementation, post-go-live optimization, and managed services aligns seamlessly with HR Path’s vision of empowering organizational growth and excellence through strategic HR solutions.

“This is a powerful step forward in our mission to be the global reference in HR transformation,” said François Boulet, Co-founder of HR Path. “Their strong reputation in the North American market and deep expertise in UKG solutions enhance our ability to deliver high-value, end-to-end HR services worldwide. This partnership reflects our continued investment in innovation, client success, and global growth.”

“PredictiveHR brings a level of UKG expertise and service excellence that perfectly complements our global HRIS strategy,” said Theodore Smith, Partner at HR Path. “Together, we’re better positioned to support clients across North America and around the world with tailored, end-to-end UKG solutions that deliver measurable results.”

“We’re incredibly proud of what we’ve built at PredictiveHR,” said James Troiano, Founder and CEO. “From day one, our focus has been on delivering exceptional value through expertise, integrity, and innovation. Joining forces with HR Path allows us to expand that mission on a global scale, while staying true to the culture and client-first mindset that made us who we are. This acquisition is not just a milestone—it’s a launchpad for even greater impact.” 

PDF:   https://mma.prnewswire.com/media/2745259/HR_Path_EN.pdf

Contact : Fabienne LATOUR – Fabienne.latour@hr-path.com

Strategic collaboration with SACEOS aims to upskill MICE professionals through hands-on certification programme

SINGAPORE, Aug. 6, 2025 /PRNewswire/ — Unearthed Productions, NTUC LearningHub (NTUC LHUB), and the Singapore Association of Convention & Exhibition Organisers and Suppliers (SACEOS) have signed a Partnership Agreement to jointly deliver a new certification programme designed to raise industry standards and build stronger audio-visual capabilities within Singapore’s MICE and hospitality sectors.

Graduates who successfully complete the course will be awarded a recognised credential — Audio Visual Specialist (AVS) — which they may append to their names and professional titles, similar to the CMP (Certified Meeting Professional) designation.

The Partnership Agreement was signed at CatchUP 2025, the annual industry gathering hosted by Unearthed Productions. This year’s edition also marked the launch of UPGroup Asia, the regional brand under Unearthed Productions, and a new MICE venue search platform for UP-managed venues designed to help clients discover unique event spaces and elevate their AVL (audio, visual, lighting) experiences across the region with integrated event management and production services

The new course, WSQ Fundamentals of Audio, Visual, and Lighting Systems, is now available through NTUC LHUB. Developed in collaboration with trainers from Unearthed Productions and endorsed by SACEOS and the Singapore Tourism Board, the course equips professionals with real-world audio, visual, and lighting (AVL) skills and provides a strong foundation for those working toward the AVS Certification.

Targeted at aspiring and experienced AV technicians, MICE professionals, and hospitality practitioners, the 16-hour course blends theory and hands-on learning using industry-grade equipment. Participants will learn how to inspect, troubleshoot, and operate AV systems in line with safety protocols and client requirements. The course is part of Singapore’s national WSQ framework, with funding support available for eligible trainees.

“We’ve seen firsthand how skilled AV professionals can transform event experiences from good to exceptional. The course uses the latest and actual industry equipment, so participants graduate with the hands-on skills that event organizers genuinely need,” said Adam Piperdy, Founder and Chief Experience Officer of Unearthed Productions.

“We are seeing a demand for AV professionals who can work with the latest technology in Singapore’s growing MICE sector. Working with Unearthed Productions gives us access to current industry practices and real-world insights. This collaboration ensures we are delivering practical, job-ready skills to meet actual market needs,” said Tay Ee Learn, Assistant Chief Executive & Chief Sector Skills Officer of NTUC LearningHub.

“Singapore Tourism Board welcomes this timely collaboration. As business events grow increasingly sophisticated, cutting-edge audio-visual expertise has become essential to delivering world-class experiences. In line with STB’s Tourism 2040 roadmap, the industry-validated AVS certification programme not only builds critical capabilities but also creates promising career pathways in this dynamic field. It also helps to strengthen Singapore’s position as the World’s Best MICE City while offering professionals the opportunity to be part of our thriving business events ecosystem, supporting our long-term vision for sustained growth in MICE tourism,” said Rachel Loh, Executive Director, Hospitality & Tourism Talent, Singapore Tourism Board.

This initiative comes at a pivotal moment when Singapore’s MICE sector demonstrates exceptional growth. The country recently achieved its best-ever position on the ICCA Worldwide City Rankings, placing among the world’s premier business events destinations. With the Singapore Tourism Board targeting a three-fold increase in MICE tourism receipts by 2040, skilled Audio Visual professionals are increasingly critical to capturing this high-value segment.

This certification course directly addresses that need by developing the technical expertise essential for delivering world-class events, reflecting Unearthed Productions’ commitment to pushing industry standards forward through both exceptional event delivery and professional skills development.

Course registration is now open via NTUC LHUB.

About Unearthed Productions

Unearthed Productions is a full-service event agency based in Singapore, delivering event experiences in the region. Empowered by a team of creators, strategists, and experts who are deeply passionate about content, audience engagement, and event technology, Unearthed Productions delivers a complete suite of event solutions that allow event organisers to seamlessly execute award-winning event experiences. Producing hundreds of event experiences for thousands of audiences annually, Unearthed Productions is the trusted partner of both organisations and venue owners in the region.

About NTUC LearningHub

NTUC LearningHub is the leading Continuing Education and Training provider in Singapore which aims to transform the lifelong employability of working people. Since our corporatisation in 2004, we have been working with employers and individual learners to provide learning solutions in areas such as Infocomm Technology, Generative AI & Cloud, Healthcare, Retail & Food Services, Employability & Literacy, Business Excellence, Workplace Safety & Health, Security, Human Resources & Coaching and Foreign Workers Training.

To date, NTUC LearningHub has helped over 34,000 organisations and achieved more than 3.2 million training places across more than 1,000 courses with a pool of about 1,000 certified trainers. As a Total Learning Solutions provider to organisations, we also forge partnerships to offer a wide range of relevant end-to-end training. Besides in-person training, we also offer instructor-led virtual live classes (VLCs) and asynchronous online learning. The NTUC LearningHub Learning eXperience Platform (LXP) — a one-stop online learning platform — offers timely, bite-sized and quality content for learners to upskill anytime and anywhere. Beyond learning, LXP also serves as a platform for jobs and skills development for both workers and companies.

For more information, visit www.ntuclearninghub.com.

About SACEOS

The Singapore Association of Convention & Exhibition Organisers & Suppliers (SACEOS) was established in 1979 as the national trade association for the MICE (Meetings, Incentives, Conventions, Exhibitions, and Events) industry. As the voice and champion of the sector, SACEOS works closely with government and industry stakeholders to promote best practices, develop talent, and strengthen Singapore’s position as a global events hub.

Media Contacts

Unearthed Productions

Josiah Eufemio
Marketing and Communications Lead
josiah_eufemio@upgroup.asia

NTUC LearningHub

Steven Lee
Senior Executive, Brand & Communications
steven.lee@ntuclearninghub.com

Zulaikha Zulkiflee
Senior Manager, Brand & Communications
zulaikha@ntuclearninghub.com

HONG KONG, Aug. 6, 2025 /PRNewswire/ — Bayes Labs team announces that Bayes Market, the prediction platform launched in July pioneering the next wave of decentralized information infrastructure, has secured $2 million strategic investment from a group of investors. The investors include institutional participation from Singapore’s GreenVision Fund, Jkapital Ltd., and Bearcat, alongside a prominent U.S. public company chairman. This diverse investor group shares a unified conviction: prediction markets represent a transformational shift in how society generates, exchanges, and values information.

These funds will accelerate Bayes Market’s product development, regional expansion, and user growth—particularly across Asia, where social and cultural dynamics align naturally with prediction markets. According to the CEO of GreenVision, “Prediction markets are not just a trend—they are the future of how societies find a shared-reality in complex world. Bayes team has the right vision to scale this movement.”

Mass Adoption Underway

The year 2025 marks a turning point for the prediction market industry. Polymarket’s integration with X and Kalshi’s $2B valuation signal that the industry is moving towards the mainstream. As trust in centralized narratives erode, prediction markets offer a credible, participatory alternative—surfacing diverse viewpoints and aligning incentives for individual expression.

Prediction markets were never by nature solely for crypto-native users. Human beings are inherently driven to predict. Whether guessing the outcome of a reality show or speculating on political developments, people engage in informal forecasting daily. Prediction markets formalize this instinct, offering structure, visibility, and rewards. They are not tools for speculators alone—they are an evolution of how people interact with real-world uncertainty.

Bayes Market distinguishes itself by focusing on intuitive design, culturally relevant markets across Asia and a strong emphasis on user empowerment. These features enable a familiar, social, and gamified experience—they are social signals embedded in daily life. 

A New Intelligence Infrastructure for a Decentralized Future

As demand grows for open, transparent, and decentralized systems, prediction markets are poised to become a core infrastructure of the information economy. Bayes Market is not just building a product—it is building a public good: a participatory framework for decentralized intelligence. 

In an age defined by uncertainty, Bayes Market innovates prediction markets holding the belief that they are not an anomaly of crypto—they are the natural evolution of how society as a whole engages with the future.

PANAMA CITY, Aug. 6, 2025 /PRNewswire/ — BingX, a leading cryptocurrency exchange and Web3 AI company, successfully wrapped up its participation at GM Vietnam 2025, one of Southeast Asia’s largest blockchain gatherings. Vivien Lin, Chief Product Officer at BingX, delivered a keynote speech outlining BingX’s vision for the future of Web3 and AI, and detailed how BingX’s AI Evolution strategy is delivering more innovative and accessible experiences for users.

Vivien emphasized that the next chapter of digital assets will not be driven by speculation or hype, but by intelligence. By breaking down common barriers such as fragmented tools, information overload, and lack of confidence, BingX AI learns and grows together with its users — creating what BingX defines as financial dignity —  empowering them to make confident, informed decisions without being hindered by complexity.

Backed by a $300 million investment over three years, BingX’s AI Evolution strategy encompasses the establishment of the BingX AI Institute and the fostering of AI-driven Web3 projects through its arms like BingX Labs, reaffirming BingX’s long-term vision: to make digital assets not only accessible, but intelligent — creating a trading experience that is real-time, adaptive, and built around users’ needs.

Speaking of BingX’s vision for the market and the industry, Vivien commented: “Vietnam is emerging as one of Asia’s most dynamic blockchain communities, and events like GM Vietnam show how quickly the industry is evolving. This year, we shared how AI can bring greater dignity and agency to digital asset trading by making it more intelligent, accessible, and user-driven. BingX is committed to applying this vision not only globally, but here in Vietnam, supporting the community with innovative AI-powered tools and long-term expertise.”

Looking ahead, BingX will continue advancing its AI-powered trading solutions while deepening its roots in Vietnam and the broader Southeast Asia region. With a focus on user-centric innovation, strategic partnerships, and localized support, BingX remains committed to shaping a more intelligent, inclusive, and empowered future for digital asset traders worldwide.

About BingX 

Founded in 2018, BingX is a leading crypto exchange and Web3 AI company, serving a global community of over 20 million users. With a comprehensive suite of AI-powered products and services, including derivatives, spot trading, and copy trading, BingX caters to the evolving needs of users across all experience levels, from beginners to professionals. Committed to building a trustworthy and intelligent trading platform, BingX empowers users with innovative tools designed to enhance performance and confidence. In 2024, BingX proudly became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports sponsorship.

For more information please visit: https://bingx.com/

TAIPEI, Aug. 6, 2025 /PRNewswire/ — Taiwanese jewelry artist Karjengon Wu has forged a distinctive design language that seamlessly integrates art, culture, aesthetics, and brand management. With this multifaceted creative power, he has risen to prominence in the international jewelry scene. His works are not merely accessories, but wearable art pieces—cultural vessels that transcend borders—earning acclaim and admiration across the global fashion world.

Wu is the founder of T.THREE Jewelry, a brand he co-created with design partner Yi-Wen Lin. Together, they have produced numerous captivating collections favored by global dignitaries and social elites. Notable collectors of his work include Palau‘s Goodwill Ambassador Ms. Chia-Ju Tsai, Mrs. Paine, wife of the Haitian Ambassador, and Abigail Beatrice, First Secretary of the Eswatini Embassy—each representing the international appeal of Wu’s creations.

Mayor Bertrick of Moret-sur-Loing, France, personally collected one of Wu’s signature pieces, praising its exquisite craftsmanship and the profound beauty of Eastern design. He described the work as a “cultural bridge” between France and Taiwan. Madame Dominique, Chair of the French Association of Painters and Calligraphers, also collected Wu’s award-winning piece “Elegant Orchid Spirit“, which received honors at the International Orchid Handicraft Competition—further affirming Wu’s artistic impact on the global stage.

Wu’s creations have also been embraced by the fine art community. Ho Wen-Chi, a nationally honored painter recognized by Taiwan’s Ministry of Culture, is a devoted wearer of Wu’s pieces, commending the harmonious balance of colors and gemstones. The late master of ink painting, Lee Chi-Mao, also collected Wu’s jewelry and inscribed a personalized calligraphy piece in tribute:
“Mr. Karjengon—Master of Exquisite Eastern Craftsmanship,” adding a layer of artistic resonance to Wu’s design legacy.

Karjengon Wu’s design language is highly distinctive. Whether working in minimalism, Baroque, naturalism, futurism, or ethnic styles, each collection presents a uniquely interpreted aesthetic. He boldly incorporates unconventional materials such as wood, shells, resin, and recycled elements, utilizing wax carving, micro-sculpting, and mixed media to break free from traditional jewelry frameworks.

His works have been showcased at numerous international exhibitions in cities such as Paris, Beijing, Chongqing, and Tokyo, highlighting Taiwan’s creative spirit and rich design diversity on a global scale—enhancing the island’s visibility and influence in the realm of cultural diplomacy.

Selected International Exhibitions & Events:

• 2012 – Greater China Jewelry Designers Joint Exhibition, Beijing, China (Taiwan Representative)
• 2012 – China International Jewelry Masters Forum, Beijing Caibai
• 2013 – Shenzhen International Cultural Industries Fair, Jewelry Pavilion
• 2014 – East-West Art Exchange Exhibition at the Louvre, Paris
• 2014 – Awarded artist in the Taiwan Tour of the Louvre’s East-West Art Exhibition (Kaohsiung)
• 2015 – International Art Expo at Pierre Cardin Art Center, Paris – attended by Laotian princess and 8th arrondissement mayor Jeanne d’Hauteserre
• 2017 – Jewelry showcase and forum hosted by China’s Taiwan Affairs Office in Chengdu
• 2019 – Karjengon Wu & Yi-Wen Lin Jewelry Duo Exhibition and Runway Show at Far Eastern Museum THE ONE
• 2022 – Cross-disciplinary showcase combining traditional cheongsam and jewelry at Lin Palace, Kaohsiung
• 2023 – T.THREE Jewelry Show at Kaohsiung Marriott Hotel – featuring Miss Asia Taiwan 3rd runner-up Yu Hsiao-Han wearing Wu’s Louvre gold-winning piece
• 2024 – Jewelry runway show at the Neo-Classical Ladies Club President Handover Ceremony at Lin Palace
• 2025 – Karjengon Wu & Yi-Wen Lin’s stunning runway showcase at Lin Palace again highlighted in a prestigious handover ceremony

A special highlight: Former French Prime Minister Jean-Pierre Raffarin personally visited Wu’s exhibition at the Louvre in 2014 and gave high praise to his jewelry artworks.

Staying true to his mission—“Let Taiwanese design shine confidently on the global stage“—Karjengon Wu continues to root his work in Eastern aesthetics while merging them with contemporary creative expressions. His culturally enriched jewelry art continues to captivate collectors and audiences around the world.

• Brand Information

T.THREE Jewelry
Facebook: https://www.facebook.com/profile.php?id=100063912950648

Original link: https://www.t3-news.com/news_detail.php?NewsID=12708&NewsTitle=%E7%8F%A0%E5%AF%B6%E8%A8%AD%E8%A8%88%E5%B8%AB%E5%90%B3%E4%BD%B3%E6%A5%A8Karjengon%E5%89%B5%E6%84%8F%E8%BB%9F%E5%AF%A6%E5%8A%9B%E5%90%B8%E5%BC%95%E5%9C%8B%E9%9A%9B%E7%9B%AE%E5%85%89

• Birelentinib (DZD8586) received Fast Track Designation from the U.S. FDA for relapsed/refractory CLL/SLL
• Supporting data from a pooled analysis of phase I/II studies of birelentinib showed an objective response rate of 84.2% in heavily pretreated CLL/SLL patients

SHANGHAI, Aug. 6, 2025 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its Birelentinib (DZD8586) for the treatment of adult patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

Patients with CLL/SLL treated with a BTK inhibitor or a BCL-2 inhibitor often relapse or progress due to two major resistance mechanisms: BTK C481X mutations and BTK-independent activation of BCR signaling pathway. No targeted therapy currently addresses both mechanisms, posing an urgent clinical challenge. Although BTK degraders have shown encouraging anti-tumor activity in early CLL/SLL clinical studies, mutation-mediated resistance has already been reported, and degrader-associated toxicities may limit their long-term clinical application.

Birelentinib is a first-in-class, non-covalent, LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration. It has high selectivity against other TEC family kinases (TEC, ITK, TXK and BMX). By targeting both BTK and LYN, it blocks both BTK-dependent and -independent BCR-signaling pathways, effectively inhibiting tumor growth of B-cell non-Hodgkin lymphomas (B-NHLs).

The Fast Track Designation is supported by data from a pooled analysis of two phase I/II studies of birelentinib in CLL/SLL patients previously treated with covalent/non-covalent BTK inhibitors and BTK degraders. The results were presented at 2025 European Hematology Association (EHA) Annual Congress and featured in oral presentations at both the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the 18th International Conference on Malignant Lymphoma (ICML).

Birelentinib demonstrated significant anti-tumor efficacy in heavily pretreated CLL/SLL patients with an objective response rate (ORR) of 84.2%, with a good safety profile. Tumor responses were observed irrespective of prior treatment with covalent/non-covalent BTK inhibitors, BTK degraders, or BCL-2 inhibitors, including in patients harboring classic BTK resistance mutations (C481X) as well as other BTK mutations, such as kinase-dead mutations. Responses were durable, with an estimated 9-month duration of response (DOR) rate of 83.3%.

“The granting of Fast Track Designation underscores the U.S. FDA’s recognition of birelentinib’s potential to address an unmet medical need in patients with CLL/SLL,” said Dr. Xiaolin Zhang, CEO of Dizal. “We look forward to working closely with the FDA to accelerate the global clinical development of birelentinib and bring this treatment option to patients as quickly as possible.”

Fast Track Designation is an FDA program designed to facilitate the development and expedite the review of drugs for serious conditions that address unmet medical needs. The designation enables for frequent FDA interactions and may allow for rolling revie, priority review, or accelerated approval if criteria are met.

About Birelentinib (DZD8586)

Birelentinib is a first-in-class, non-covalent, LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration, designed as a potential treatment option for B-cell non-Hodgkin lymphoma (B-NHL). 

While Bruton’s Tyrosine Kinase (BTK) inhibitors have been approved for the treatment of B-NHL, resistance can arise through two major mechanisms: the BTK C481X mutation and BTK-independent BCR signaling pathway activation. Currently, there is no targeted therapy available to address both resistance mechanisms, posing an urgent clinical challenge. Although BTK degraders have shown encouraging efficacy in early clinical studies, mutation-related resistance has been reported, and degrader-related toxicities may affect long-term clinical application. 

Birelentinib has high selectivity against other TEC family kinases (TEC, ITK, TXK and BMX). By targeting BTK and LYN, it blocks both BTK-dependent and -independent BCR-signaling pathways, effectively inhibiting tumor growth of B-NHLs in cell lines and in animal models. In clinical studies, birelentinib exhibits favorable PK properties, good central nervous system (CNS) permeability, complete blockade of BCR signaling, and encouraging anti-tumor efficacy with good safety and tolerability in patients with B-NHL.

In August 2025, birelentinib was granted Fast Track Designation by the U.S. FDA for the treatment of adult patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

About Dizal

Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs worldwide. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio with multiple assets in global pivotal studies and two leading assets: ZEGFROVY, approved in both the U.S. and China, and golidocitinib, approved in China. To learn more about Dizal, please visit www.dizalpharma.com, or follow us on Linkedin or X.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, and “intend” and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal’s competitive environment, and political, economic, legal, and social conditions.

Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect.

Contacts

Investor Relations: ir@dizalpharma.com
Business Development: bd@dizalpharma.com
Media Contact: pr@dizalpharma.com